Late-Stage Peritoneal Cancers And Peritoneal Metastases

The indication includes epithelial cancer, peritoneal mesothelioma, desmoplastic small round cell tumor, pseudomyxoma peritonei.
RapidSelection™  is also available through a no-cost, nationwide clinical study, and other financial assistance is available.
Contact Us

For late-stage patients and their oncologists
looking for effective treatments now

Peritoneal Cancers and Peritoneal Metastases are particularly challenging as often they go undetected until they reach an advanced stage. For those grappling with advanced cancers, standard treatments like surgery, chemotherapy, and targeted therapy may have limited effectiveness.
Late-stage cancer patients have typically failed all of the highly effective drugs given to earlier patients. They are then faced with a long list of less effective drugs, typically with population response rates of around 20%.
For each patient, it's very likely that, “hidden” within that long list of low-effectiveness drugs, a few drugs will be highly effective for that unique patient.
RapidSelection™ has solved this problem by directly testing a late-stage patient's live cancer cells against long lists of drugs to find any personalized, effective drugs.

RapidSelection™ is available in two versions

EarlyAccess
RapidSelection™ EarlyAccess measures live cancer cells against a predetermined panel of 20 FDA-approved cancer drugs.

This option requires that you share the treatment outcome data to help Travera build additional clinical evidence.

Turnaround time: 2 days from sample collection
Total drugs tested: 20 FDA-approved
Sample types: Tissue, Malignant Fluids
OpenPanel
RapidSelection™ OpenPanel measures live cancer cells against a panel of up to 20 FDA-approved cancer drugs of your choice.  

Our catalog includes over 100 FDA-approved drugs.

Turnaround time: 2 days from sample collection
Total drugs tested: up to 20 FDA-approved
Sample types: Tissue, Malignant Fluids

Drug panel for testing with RapidSelection™ EarlyAccess: Peritoneal Cancers And Peritoneal Metastases

Due to the variety of  cancers that can affect the peritoneal space, we do not have a pre-determined drug list for this category. We commonly analyze drugs used for HIPEC based treatments, and we can use our other available drug lists (colon, gastric, etc.) as a starting point to compile the right drugs for your circumstances.

We will work with you and your doctor to select the drugs that are most applicable to your unique situation.

How it works

Step 1
Order
Discuss the RapidSelection™ Test with your patient. You can contact Travera’s clinical support services to determine which testing option to prescribe.
Step 2
Sample Collection
We will ship a sample collection kit to the person indicated in the test requisition form. Once collected, the sample will reach our lab quickly via overnight shipping.
Step 3
Test results
Within the following 2 days, the test results are ready to review online or via fax. Our clinical support services are available to answer any questions.

Contact us

Please reach out to us anytime and we will respond within 24 hours.
Thank you, we have received your request and will be in touch shortly.
Something went wrong while submitting the form.
Please try again.
Contact details
RapidSelection™
by Travera, Inc.

200 Boston Ave, Suite 1500
Medford, MA 02155
United States